1. Home
  2. LFS vs CING Comparison

LFS vs CING Comparison

Compare LFS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LEIFRAS Co. Ltd. American Depositary Shares

LFS

LEIFRAS Co. Ltd. American Depositary Shares

SELL

Current Price

$2.32

Market Cap

54.2M

Sector

Real Estate

ML Signal

SELL

CING

Cingulate Inc.

HOLD

Current Price

$5.34

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFS
CING
Founded
2001
2012
Country
Japan
United States
Employees
1055
14
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.2M
64.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LFS
CING
Price
$2.32
$5.34
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
722.6K
168.9K
Earning Date
04-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.58
$3.16
52 Week High
$12.49
$11.89

Technical Indicators

Market Signals
Indicator
LFS
CING
Relative Strength Index (RSI) 57.89 57.73
Support Level $2.16 $4.80
Resistance Level $2.74 $5.15
Average True Range (ATR) 0.30 0.28
MACD 0.03 0.05
Stochastic Oscillator 18.78 94.15

Price Performance

Historical Comparison
LFS
CING

About LFS LEIFRAS Co. Ltd. American Depositary Shares

Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: